{"nct_id":"NCT03833427","title":"Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)","status":"TERMINATED","status_verified_date":"2024-11","start_date":"2019-03-18","start_date_type":"ACTUAL","primary_completion_date":"2022-06-28","primary_completion_date_type":"ACTUAL","completion_date":"2022-06-28","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["MRK"]}